Kuzu, O. F. Et Al. 2025. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma. BMC Cancer , vol.25, no.1 .

Kuzu, O. F., BÖLEK, H., Sertesen Camoz, E., Karakas, H., Sekmek, S., Sim, S., ... Isık, S.(2025). Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma. BMC Cancer , vol.25, no.1.

Kuzu, Omer Et Al. "Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma," BMC Cancer , vol.25, no.1, 2025

Kuzu, Omer F. Et Al. "Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma." BMC Cancer , vol.25, no.1, 2025

Kuzu, O. F. Et Al. (2025) . "Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma." BMC Cancer , vol.25, no.1.

@article{article, author={Omer Faruk Kuzu Et Al. }, title={Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma}, journal={BMC Cancer}, year=2025}